CoreValve Evolut R First TAVR to Receive CE Mark for Intermediate Risk Patients

This morning Medtronic plc (NYSE: MDT) announced that its recapturable and repositionable CoreValve Evolut R System has received the CE Mark to treat patients with severe aortic stenosis who are at intermediate risk for open-heart surgery, making the CoreValve Evolut R the first TAVR device to obtain approval for this patient population. Previously TAVR devices were indicated for use only in patients at high risk for surgery.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news